DICE Therapeutics, Inc. is a biopharmaceutical company developing oral therapeutic candidates for chronic diseases, particularly those related to immunology. Their DELSCAPE platform is meant to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. Their lead therapeutic candidate is DC-806, which is an oral antagonist of interleukin-17, while they also focus on immuno-oncology for antibody therapeutics.